CTLA4 and central nervous system cancer: Statistical analysis based on clinical data has shown that CTLA-4 expression is higher in patients with higher grade, isocitrate dehydrogenase (IDH)-wild-type and mesenchymal-molecular subtype gliomas compared to patients with lower grade, IDH-mutant and other molecular subtype gliomas (88).